Drug Profile


Alternative Names: GX-H9; hGH-hyFc; HL 2356; Long-acting human growth hormone - Genexine; Somatropin long-acting - Genexine/Handok

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Genexine
  • Developer Genexine; Handok Inc
  • Class Growth hormones; Hormonal replacements; Recombinant fusion proteins
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Somatotropin deficiency

Most Recent Events

  • 20 Apr 2017 Genexine completes a phase II trial in Somatotropin deficiency (In adults) in Germany, Slovakia, Hungary, Poland, South Korea, Sweden and Greece (EudraCT2014-002698-13)
  • 03 Apr 2017 Efficacy and adverse events data from phase II trials in Somatotropin deficiency presented at the 99th Annual Meeting of the Endocrine Society for Paediatric Endocrinology (ENDO-2017)
  • 16 Nov 2016 Handok and Genexine complete a phase I trial for Somatotropin deficiency in Netherlands before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top